Answers are grounded in this paper and cite their sources.
Evaluates antimicrobial activity in pathogens, implying potential for new treatments.
Peptidomic studies in HeLa cells identified the antitumoral activity of Pep5, and our group observed that coupling Pep5 to a carrier peptide (Cpp) provides antimicrobial potential. This study evaluated the antimicrobial activity of Pep5-Cpp and its derivatives (ΔC3-Pep5-Cpp and ΔN-Pep5-Cpp) and investigated their potential mechanisms of action. For Staphylococcus aureus, MIC values were 6.25 µM for Pep5-Cpp and ΔC3-Pep5-Cpp and 12.5 µM for ΔN-Pep5-Cpp. Against Candida albicans, Pep5-Cpp showed a MIC of 3.125 µM, while both derivatives presented 6.25 µM. For Aspergillus niger, MIC values were 1.56 µM for Pep5-Cpp and ΔN-Pep5-Cpp, and 25 µM for ΔC3-Pep5-Cpp. Pep5-Cpp interacted with S. aureus DNA, increased fluorescence in S. aureus, and showed no change in C. albicans. Only ΔC3-Pep5-Cpp inhibited biofilm (>50%). Microbicidal assays showed that high concentrations were needed to kill S. aureus (>100 µM), while lower concentrations completely inhibited C. albicans (<6.25 µM). In the hemolytic assay, the peptides at their MIC values did not induce measurable hemolysis. These findings indicate that Pep5-Cpp and its derivatives have antimicrobial potential and selectivity, supporting future pharmacological development.
No takes yet. Share an insight, caveat, or question.
Souto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: